↓ Skip to main content

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, February 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter
googleplus
1 Google+ user

Citations

dimensions_citation
65 Dimensions

Readers on

mendeley
98 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, February 2014
DOI 10.2147/copd.s51592
Pubmed ID
Authors

Walter Vincken, Joseph Aumann, Hungta Chen, Michelle Henley, Danny McBryan, Pankaj Goyal

Abstract

Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting β2-agonist indacaterol (IND) and the long-acting muscarinic antagonist glycopyrronium (GLY) versus IND alone in patients with moderate-to-severe COPD.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 2%
United States 1 1%
Unknown 95 97%

Demographic breakdown

Readers by professional status Count As %
Other 14 14%
Student > Master 12 12%
Researcher 12 12%
Student > Bachelor 12 12%
Student > Ph. D. Student 8 8%
Other 22 22%
Unknown 18 18%
Readers by discipline Count As %
Medicine and Dentistry 52 53%
Nursing and Health Professions 7 7%
Biochemistry, Genetics and Molecular Biology 4 4%
Agricultural and Biological Sciences 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 4 4%
Unknown 25 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#4,664,542
of 17,351,915 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#549
of 1,971 outputs
Outputs of similar age
#49,726
of 194,221 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#10
of 25 outputs
Altmetric has tracked 17,351,915 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,971 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,221 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.